The funding will support the development of an AI-powered platform. Credit: tilialucida / Shutterstock.com.

Every Cure has received a three-year $48.3m contract from the US Advanced Research Projects Agency for Health (ARPA-H), marking a significant federal investment in drug repurposing.

The funding will support the development of an artificial intelligence (AI)-powered platform, ML/AI-enabled Therapeutic Repurposing In eXtended uses (MATRIX) to enhance the potential of existing therapies to treat a broader range of diseases.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Every Cure plans to leverage the ARPA-H funding to create an open-source drug repurposing database and build a portal for contributions from researchers, physicians and patients.

The company also intends to publicly launch predictive efficacy scores for all therapies against all diseases and choose drugs to address neglected ailments.

Traditional drug discovery and repurposing typically focus on one disease or drug, limiting the scope of potentially life-saving treatments.

See Also:

Every Cure’s approach will analyse a range of drugs and diseases simultaneously, quantifying the strength of links to identify promising new treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The MATRIX project builds on previous work by the National Center for Advancing Translational Sciences (NCATS) Biomedical Data Translator Program.

Last year, Every Cure collaborated with NCATS-funded investigator David Koslicki at Penn State University, and other Translator Program members to create pilot rankings for all 3,000 drugs approved by the FDA for all human diseases.

By using new AI techniques to assess worldwide biomedical knowledge, the company aims to detect 100 potential therapy opportunities over the five years to 2028. It plans to progress 25 of them into further research, including studies.

Early promising leads include arginine to treat sickle cell disease, folinic acid for autism spectrum disorder and bosutinib for amyotrophic lateral sclerosis.

The latest development comes after Every Cure secured funding from the Chan Zuckerberg Initiative, the Elevate Prize Foundation, Flagship Pioneering and Lyda Hill Philanthropies.

Every Cure co-founder and CEO Grant Mitchell stated: “Society’s greatest life-saving resource is the trove of medicines we already have. Leveraging a systematic, disease-agnostic approach for drug repurposing enables us to rapidly unlock new diseases they can treat and confirm the validity of AI discoveries in patients.

“We’re excited to make our research tools available to the public, advancing data-driven discovery and offering hope to patients worldwide.”